These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 2910527)

  • 1. In vivo distribution of a carcinogenic hepatic peroxisome proliferator: whole-body autoradiography of [14C]ciprofibrate in the mouse.
    Waddell WJ; Marlowe C; Rao MS; Reddy JK
    Carcinogenesis; 1989 Jan; 10(1):221-3. PubMed ID: 2910527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of peroxisome proliferation and hepatic tumours in C57BL/6N mice by ciprofibrate, a hypolipidaemic compound.
    Rao MS; Dwivedi RS; Subbarao V; Reddy JK
    Br J Cancer; 1988 Jul; 58(1):46-51. PubMed ID: 2901849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution of [2-14C]merbarone in mice by autoradiography of whole-body cryosections.
    Kemmenoe BH; Malspeis L
    Cancer Res; 1987 Feb; 47(4):1135-42. PubMed ID: 3802094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the peroxisome proliferator ciprofibrate on hepatic DNA synthesis and hepatic composition following partial hepatectomy in rats.
    Srinivasan SR; Chow CK; Glauert HP
    Toxicology; 1990 Jun; 62(3):321-32. PubMed ID: 2389247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irreversible inhibition of hepatic glutathione S-transferase by ciprofibrate, a peroxisome proliferator.
    Awasthi YC; Singh SV; Goel SK; Reddy JK
    Biochem Biophys Res Commun; 1984 Sep; 123(3):1012-8. PubMed ID: 6487318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of liver cell proliferation during ciprofibrate-induced hepatocarcinogenesis.
    Yeldandi AV; Milano M; Subbarao V; Reddy JK; Rao MS
    Cancer Lett; 1989 Sep; 47(1-2):21-7. PubMed ID: 2636030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ciprofibrate and 2-[5-(4-chlorophenyl)pentyl]oxirane-2-carboxylate (POCA) on the distribution of carnitine and CoA and their acyl-esters and on enzyme activities in rats. Relation between hepatic carnitine concentration and carnitine acetyltransferase activity.
    Bhuiyan AK; Bartlett K; Sherratt HS; Agius L
    Biochem J; 1988 Jul; 253(2):337-43. PubMed ID: 3178716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effect of antioxidants ethoxyquin and 2(3)-tert-butyl-4-hydroxyanisole on hepatic tumorigenesis in rats fed ciprofibrate, a peroxisome proliferator.
    Rao MS; Lalwani ND; Watanabe TK; Reddy JK
    Cancer Res; 1984 Mar; 44(3):1072-6. PubMed ID: 6692393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of initiating activity of the peroxisome proliferator ciprofibrate in two-stage hepatocarcinogenesis.
    Glauert HP; Clark TD
    Cancer Lett; 1989 Feb; 44(2):95-100. PubMed ID: 2920376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the peroxisome proliferator ciprofibrate on lipid peroxidation and 8-hydroxydeoxyguanosine formation in transgenic mice with elevated hepatic catalase activity.
    Nilakantan V; Spear BT; Glauert HP
    Free Radic Biol Med; 1998 Jun; 24(9):1430-6. PubMed ID: 9641260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome proliferator-induced hepatocarcinogenesis: levels of activating and detoxifying enzymes in hepatocellular carcinomas induced by ciprofibrate.
    Rao MS; Kokkinakis DM; Subbarao V; Reddy JK
    Carcinogenesis; 1987 Jan; 8(1):19-23. PubMed ID: 3100085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The pharmacokinetics of antilipemic agents. 5. Is 2-(4-hydroxyphenoxy)-2-methylpropionic acid a metabolite of the antilipemic ciprofibrate?].
    Oelschläger H; Rothley D; Hellwich KH; Schmidt W
    Arch Pharm (Weinheim); 1989 Jun; 322(6):337-42. PubMed ID: 2774869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of alpha-1 adrenergic receptor inhibits hepatic DNA synthesis stimulated by tumor promoters.
    Tsai WH; Cruise JL; Michalopoulos GK
    Carcinogenesis; 1989 Jan; 10(1):73-8. PubMed ID: 2463115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of dietary vitamin E on the development of altered hepatic foci and hepatic tumors induced by the peroxisome proliferator ciprofibrate.
    Glauert HP; Beaty MM; Clark TD; Greenwell WS; Tatum V; Chen LC; Borges T; Clark TL; Srinivasan SR; Chow CK
    J Cancer Res Clin Oncol; 1990; 116(4):351-6. PubMed ID: 1975253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of gamma-glutamyltranspeptidase activity in lung metastasis in rats with hepatocellular carcinomas induced by ciprofibrate, a peroxisome proliferator.
    Milano M; Reddy JK; Prasad JD; Rao MS
    Cancer Lett; 1987 Dec; 38(1-2):65-71. PubMed ID: 2891433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased resistance of peroxisome proliferator-induced hepatic lesions to iron overload in rats.
    Rao MS; Subbarao V; Reddy JK
    Cancer Lett; 1986 Jul; 32(1):33-9. PubMed ID: 3742486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The pharmacokinetics of hypolipemic agents. 6. Is 2-(4-(2,2-dichlorocyclopropyl)-phenoxy)-propane a metabolite of the hypolipemic ciprofibrate?].
    Oelschläger H; Rothley D; Hellwich KH; Schmidt W
    Arch Pharm (Weinheim); 1989 Oct; 322(10):629-32. PubMed ID: 2624522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of gastric antisecretory effects of phenoxyisobutyrate derivatives in the rat and the mouse.
    Eason CT; Pattison A; Howells DD; Spencer AJ; Bonner FW
    Scand J Gastroenterol; 1988 Nov; 23(9):1063-71. PubMed ID: 3247588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate.
    Ferry N; Bernard N; Pozet N; Gardes E; Cuisinaud G; Labeeuw M; Zech PY; Sassard J
    Br J Clin Pharmacol; 1989 Dec; 28(6):675-81. PubMed ID: 2611089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacokinetics of antilipemic agents. 4. Biotransformation of the antilipemic agent ciprofibrate (2-(4-(2,2-dichlorcyclopropyl)-phenoxy)-2-methylpropionic acid)].
    Oelschläger H; Rothley D; Schmidt W
    Arch Pharm (Weinheim); 1988 Jun; 321(6):367-70. PubMed ID: 3178437
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.